Endonovo THERAPEUTICS, Inc. (ENDV) intrinsic value & 10-year financials
Endonovo THERAPEUTICS, Inc. (ENDV) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 21.8% a year to $135.4K, with an average return on invested capital of 111.0%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.00
- Revenue (FY2022)
- $135.4K
- Revenue growth (10-yr CAGR)
- 21.8%
- ROIC (10-yr avg)
- 111.0%
- Free cash flow (FY2022)
- —
ENDV 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2022 | $135.4K | -$18.5M | — | — | -2411.7% | 109.9% |
| FY2021 | $73.1K | -$3.1M | — | — | -3045.7% | 38.4% |
| FY2020 | $165.8K | -$395.6K | — | — | -1756.5% | 3.7% |
| FY2019 | $310.2K | -$17.3M | — | -$2.5M | -1228.1% | 200.6% |
| FY2018 | $83.3K | -$6.4M | — | -$2.9M | -4995.3% | 218.4% |
| FY2017 | — | -$10.8M | — | — | — | 281.1% |
| FY2016 | — | -$5.3M | — | — | — | 81.8% |
| FY2015 | $4.3K | -$5.1M | — | -$1.0M | -58569.6% | 46.7% |
| FY2014 | $24.2K | -$959.5K | — | -$909.3K | -9057.6% | 70.5% |
| FY2013 | $22.9K | -$2.9M | — | — | -10607.6% | 58.8% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
ENDONOVO THERAPEUTICS, INC. is a consistent compounder, expanding top-line revenue at 21.8% annually over the past decade.
ENDONOVO THERAPEUTICS, INC. has earned high returns on invested capital, averaging 41.7% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
ENDONOVO THERAPEUTICS, INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, ENDONOVO THERAPEUTICS, INC. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment.